You will begin taking rilzabrutinib tablets orally. This medication is being tested for immune thrombocytopenia (ITP), a condition affecting blood platelet levels.

Your initial platelet count will be measured to establish a baseline.

Your platelet count will be checked regularly to monitor for response to treatment.

A positive response is indicated by achieving a platelet count of at least 50,000/μL, or between 30,000/μL and 50,000/μL with at least double your starting count.

These measurements must be recorded at least 5 days apart.

Platelet counts will continue to be checked every 2 weeks.

Your bleeding symptoms will be evaluated using a standardized scale.

If you are taking corticosteroids, your dose may be adjusted based on your response to treatment.

During the final 12 weeks, you must maintain the target platelet levels for at least half of your scheduled check-ups.

A minimum of 4 valid visits showing maintained platelet counts is required.

Your response will be considered successful if you maintain these levels without requiring emergency treatment.

The study will evaluate if the medication provided a lasting increase in your platelet count.

Final assessments will include blood tests and evaluation of any changes in bleeding symptoms.

Your corticosteroid use will be reviewed to determine if the dose was reduced by 50% or to less than 5 mg.